SYNJ2 is a novel and potential biomarker for the prediction and treatment of cancers: from lung squamous cell carcinoma to pan-cancer

BACKGROUND: The roles and clinical values of synaptojanin 2 (SYNJ2) in lung squamous cell carcinoma (LUSC) remain unclear. METHODS: A total of 2824 samples from multi-center were collected to identify the expression of SYNJ2 in LUSC by using Wilcoxon rank-sum test, t-test, and standardized mean diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Wei, Li, Guo-Sheng, Gao, Li, Lu, Hui-Ping, Zhou, Hua-Fu, Kong, Jin-Liang, Chen, Gang, Xia, Shuang, Wei, Hong-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112447/
https://www.ncbi.nlm.nih.gov/pubmed/35581615
http://dx.doi.org/10.1186/s12920-022-01266-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112447/
https://www.ncbi.nlm.nih.gov/pubmed/35581615
http://dx.doi.org/10.1186/s12920-022-01266-0

Ejemplares similares